Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Subst Abuse Treat. 2014 Jul;47(1):27-34. doi: 10.1016/j.jsat.2014.02.003. Epub 2014 Mar 3.

Abuse and diversion of buprenorphine sublingual tablets and film.

Author information

  • 1Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, 777 Bannock Street, MC 0180, Denver, CO, 80204, USA. Electronic address: eric.lavonas@rmpdc.org.
  • 2Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, 777 Bannock Street, MC 0180, Denver, CO, 80204, USA. Electronic address: geoff.severtson@rmpdc.org.
  • 3Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, 777 Bannock Street, MC 0180, Denver, CO, 80204, USA. Electronic address: erin.martinez@rmpdc.org.
  • 4Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, 777 Bannock Street, MC 0180, Denver, CO, 80204, USA. Electronic address: Becki.Bucher-Bartelson@rmpdc.org.
  • 5Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, 777 Bannock Street, MC 0180, Denver, CO, 80204, USA. Electronic address: marie-claire.lelait@rmpdc.org.
  • 6Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, 777 Bannock Street, MC 0180, Denver, CO, 80204, USA. Electronic address: jody.green@rmpdc.org.
  • 7Venebio Group, LLC, 7400 Beaufont Springs Drive, Suite 300, Richmond, VA 23225, USA. Electronic address: lenn.murrelle@venebio.com.
  • 8Department of Psychiatry, Washington University in St. Louis, One Brookings Drive, Campus Box 8134, St. Louis, MO 63130 USA. Electronic address: cicerot@psychiatry.wustl.edu.
  • 9Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, 2 NE 40th Street, Suite 404, Miami, FL 33137 USA. Electronic address: steven.kurtz@nova.edu.
  • 10Institute for Treatment and Services Research, National Development and Research Institutes, 71 West 23rd Street, 4th floor, New York, NY 10010 USA. Electronic address: rosenblum@ndri.org.
  • 11Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, 2 NE 40th Street, Suite 404, Miami, FL 33137 USA. Electronic address: surratt@nova.edu.
  • 12Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, 777 Bannock Street, MC 0180, Denver, CO, 80204, USA. Electronic address: richard.dart@rmpdc.org.

Abstract

Buprenorphine abuse is common worldwide. Rates of abuse and diversion of three sublingual buprenorphine formulations (single ingredient tablets; naloxone combination tablets and film) were compared. Data were obtained from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Poison Center, Drug Diversion, Opioid Treatment (OTP), Survey of Key Informants' Patients (SKIP), and College Survey Programs through December 2012. To control for drug availability, event ratios (rates) were calculated quarterly, based on the number of patients filling prescriptions for each formulation ("unique recipients of a dispensed drug," URDD) and averaged and compared using negative binomial regression. Abuse rates in the OTP, SKIP, and College Survey Programs were greatest for single ingredient tablets, and abuse rates in the Poison Center Program and illicit diversion rates were greatest for the combination tablets. Combination film rates were significantly less than rates for either tablet formulation in all programs. No geographic pattern could be discerned.

Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

Buprenorphine; Drug abuse; Drug formulations; Substance-related disorders

PMID:
24680219
[PubMed - in process]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk